Many cases of ALK, ROS‐1, and BRAF mutation/translocation‐positive NSCLC have not been tested in clinical practice, and it is possible that some of the unknown cases may have driver mutation/translocation. This evidence concerns the gene ALK and non-small cell lung carcinoma.